Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4154725 | 0.82 | MAPK1 (0.49) | KMT2AMEN1HTTTSHRMAPK1 | |
| SCHEMBL10182776 | 0.78 | TSHR (0.38) | KMT2AMEN1HTTTSHRMAPK1 | |
| SCHEMBL14395771 | 0.76 | KDM4E (0.44) | KMT2AMEN1MAPK1ESR2POLB | |
| SCHEMBL25062589 | 0.75 | NPC1 (0.40) | KMT2AHTTTSHRPOLBSMN1; SMN2 | |
| SCHEMBL11836198 | 0.75 | LMNA (0.49) | KMT2AMEN1HTTTSHRMAPK1 | |
| SCHEMBL701960 | 0.75 | HSD17B10 (0.59) | KMT2AMEN1HTTTSHRMAPK1 | |
| SCHEMBL1390607 | 0.74 | KMT2A (0.55) | KMT2AMEN1HTTTSHRMAPK1 | |
| SCHEMBL11830174 | 0.74 | LMNA (0.51) | KMT2AMEN1HTTTSHRMAPK1 | |
| SCHEMBL6682006 | 0.74 | CYP1A1 (0.39) | TSHRMAPK1HSD17B10HPGDALDH1A1 | |
| SCHEMBL28474528 | 0.73 | MAPK1 (0.55) | KMT2AMEN1HTTTSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133178-B2 | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease | PROXIMAGEN LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133178-B2 | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease | PROXIMAGEN LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-9133178-B2 | Alpha-7 nicotinic receptor modulators for the treatment of pain, a psychotic disorder, cognitive impairment or alzheimer'S disease | PROXIMAGEN LIMITED (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | PROXIMAGEN LIMITED (GB) | 2013-11-21 | — | — | US | disclosed |
| US-20070099991-A1 | SELECTIVE RXR LIGANDS | HAFFNER CURT D | 2007-05-03 | — | — | US | disclosed |
| US-7173134-B2 | Selective RXR ligands | SMITHKLINE BEECHAM CORPORATION (US) | 2007-02-06 | — | — | US | disclosed |
| US-20040198980-A1 | Selective rxr ligands | SMITHKLINE BEECHAM CORPORATION | 2004-10-07 | — | — | US | disclosed |
| EP-1430042-A2 | BICYCLIC HETEROCYCLES AS RXR LIGANDS | SmithKline Beecham Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027090-A2 | BICYCLIC HETEROCYCLES AS RXR LIGANDS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198980-A1 | Selective rxr ligands | RXRA, RXRB, RXRG | KMT2A 2862/4885MEN1 4876/4885HTT 3016/4885 |
| US-20130310380-A1 | ALPHA-7 NICOTINIC RECEPTOR MODULATORS FOR THE TREATMENT OF PAIN, A PSYCHOTIC DISORDER, COGNITIVE IMPAIRMENT OR ALZHEIMER'S DISEASE | CHRNA7, CHRNA10, CHRNA5 | KMT2A 2700/4885MEN1 4437/4885HTT 955/4885 |
| US-20070099991-A1 | SELECTIVE RXR LIGANDS | RXRB, RXRA, RXRG | KMT2A 2821/4885MEN1 4873/4885HTT 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.